Yuki Fujiwara Selected Research

nafamostat

1/2018	Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells.
1/2016	Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
2/2015	Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
9/2013	Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
6/2013	Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
2/2013	Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
1/2013	Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.
11/2012	Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
9/2011	Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
7/2011	Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuki Fujiwara Research Topics

Disease

38	Neoplasms (Cancer) 10/2022 - 09/2009
19	Pancreatic Neoplasms (Pancreatic Cancer) 10/2020 - 10/2010
9	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2011
6	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 09/2009
4	Carcinoma (Carcinomatosis) 01/2016 - 11/2012
3	Lymphatic Metastasis 01/2021 - 05/2017
3	Inflammation (Inflammations) 01/2019 - 09/2016
3	Adenocarcinoma 01/2017 - 09/2015
2	Carcinogenesis 10/2022 - 07/2016
2	Margins of Excision 11/2021 - 01/2021
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2021
2	Ascites 01/2018 - 11/2012
2	Pancreatic Fistula (Pancreatic Fistulas) 11/2016 - 01/2015
2	Colorectal Neoplasms (Colorectal Cancer) 06/2013 - 04/2012
1	Melanoma (Melanoma, Malignant) 10/2022
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 06/2022
1	Thrombocytopenia (Thrombopenia) 06/2022
1	Wilms Tumor (Wilm's Tumor) 04/2022
1	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2022
1	Hematologic Neoplasms (Hematological Malignancy) 02/2022
1	Developmental Disabilities (Developmental Disability) 01/2022
1	Pleural Effusion (Pleural Effusions) 01/2021
1	Heart Arrest (Cardiac Arrest) 01/2021
1	Hemorrhage 01/2021
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2021
1	Bradycardia 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Leukemia 01/2021
1	Philadelphia Chromosome 01/2021
1	Malignant Pleural Effusion 01/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 09/2020
1	Agammaglobulinemia (Hypogammaglobulinemia) 09/2020
1	Cytopenia 09/2020
1	Type 2 Diabetes Mellitus (MODY) 07/2019
1	Multiple Myeloma 12/2018

Drug/Important Bio-Agent (IBA)

12	nafamostatIBA 01/2018 - 10/2010
6	C-Reactive ProteinIBA 01/2021 - 11/2012
5	AlbuminsIBA 01/2021 - 09/2016
5	Gemcitabine FDA Link 01/2018 - 11/2012
5	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 01/2016 - 10/2010
5	AntigensIBA 12/2015 - 04/2012
4	Indocyanine Green (Cardio-Green)FDA LinkGeneric 11/2021 - 12/2010
4	Pharmaceutical PreparationsIBA 01/2021 - 07/2016
4	Indicators and Reagents (Reagents)IBA 01/2018 - 09/2015
4	NF-kappa B (NF-kB)IBA 01/2016 - 10/2010
4	CarbohydratesIBA 09/2014 - 04/2012
3	Monoclonal AntibodiesIBA 01/2021 - 12/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 09/2011
3	Interleukin-8 (Interleukin 8)IBA 07/2016 - 09/2011
3	Thromboplastin (Tissue Factor)IBA 04/2016 - 09/2015
3	Carcinoembryonic AntigenIBA 09/2013 - 04/2012
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2013 - 07/2011
2	Rituximab (Mabthera)FDA Link 06/2022 - 09/2020
2	Messenger RNA (mRNA)IBA 04/2022 - 01/2021
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2022 - 01/2021
2	CytokinesIBA 01/2021 - 03/2016
2	Proteins (Proteins, Gene)FDA Link 09/2020 - 12/2017
2	Immunoglobulin G (IgG)IBA 09/2020 - 12/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2017 - 01/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2013 - 05/2011
1	Chemokine ReceptorsIBA 10/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2022
1	Immune Checkpoint InhibitorsIBA 10/2022
1	ChemokinesIBA 10/2022
1	obinutuzumabIBA 06/2022
1	Bendamustine Hydrochloride FDA Link 06/2022
1	Chimeric Antigen ReceptorsIBA 02/2022
1	perfluorooctaneIBA 01/2022
1	Fetal Proteins (Fetoprotein)IBA 11/2021
1	Insulin-Like Growth Factor Binding ProteinsIBA 01/2021
1	Alkylating AgentsIBA 01/2021
1	Inotuzumab OzogamicinIBA 01/2021
1	Nicotine FDA Link 01/2021
1	blinatumomabIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	fludarabineIBA 01/2021
1	Immunoglobulin IsotypesIBA 09/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 07/2019
1	Peptides (Polypeptides)IBA 12/2018
1	pomalidomideIBA 12/2018
1	Thalidomide (Thalomid)FDA Link 12/2018
1	Glycogen Synthase (Synthase I)IBA 01/2018

Therapy/Procedure

15	Therapeutics 10/2022 - 09/2009
11	Drug Therapy (Chemotherapy) 06/2022 - 04/2012
9	Pancreaticoduodenectomy 01/2019 - 06/2013
6	Blood Transfusion (Blood Transfusions) 10/2013 - 09/2009
5	Immunotherapy 10/2022 - 03/2016
3	Hematopoietic Stem Cell Transplantation 04/2022 - 09/2020
3	Neoadjuvant Therapy 10/2020 - 02/2015
3	Combination Drug Therapy (Combination Chemotherapy) 09/2013 - 05/2011
2	Adjuvant Chemotherapy 10/2017 - 05/2017
2	Splenectomy 12/2016 - 01/2014
2	Pancreatectomy 12/2016 - 10/2013
2	Subcutaneous Injections 09/2013 - 02/2013
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 04/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2022
1	Electrocoagulation (Electrocautery) 01/2021
1	Salvage Therapy 01/2021
1	Argon Plasma Coagulation 01/2021